-
公开(公告)号:US20110144019A1
公开(公告)日:2011-06-16
申请号:US12992667
申请日:2009-05-15
申请人: Elaine Unemori , Sam L. Teichman , Thomas Dschietzig , Dennis R. Stewart , Martha J. Whitehouse
发明人: Elaine Unemori , Sam L. Teichman , Thomas Dschietzig , Dennis R. Stewart , Martha J. Whitehouse
CPC分类号: A61K38/2221 , A61K9/0019 , C07K14/64 , A61K2300/00
摘要: The present disclosure relates to methods for treating human subjects afflicted with chronic heart failure. The methods described herein employ administration of relaxin.
摘要翻译: 本公开涉及治疗患有慢性心力衰竭的人类受试者的方法。 本文描述的方法使用松弛素的施用。
-
2.
公开(公告)号:US20140005112A1
公开(公告)日:2014-01-02
申请号:US13939648
申请日:2013-07-11
IPC分类号: A61K38/22
CPC分类号: A61K38/2221 , A61K9/0019 , C07K14/64 , A61K2300/00
摘要: The present disclosure relates to methods for treating human subjects afflicted with chronic heart failure. The methods described herein employ administration of relaxin.
摘要翻译: 本公开涉及治疗患有慢性心力衰竭的人类受试者的方法。 本文描述的方法使用松弛素的施用。
-
3.
公开(公告)号:US20160287672A1
公开(公告)日:2016-10-06
申请号:US15137054
申请日:2016-04-25
CPC分类号: A61K38/2221 , A61K9/0019 , C07K14/64 , A61K2300/00
摘要: The present disclosure relates to methods for treating human subjects afflicted with chronic heart failure. The methods described herein employ administration of relaxin.
摘要翻译: 本公开涉及治疗患有慢性心力衰竭的人类受试者的方法。 本文描述的方法使用松弛素的施用。
-
公开(公告)号:US20140328900A1
公开(公告)日:2014-11-06
申请号:US14234919
申请日:2012-08-03
IPC分类号: C07K14/64
摘要: A process for preparing human relaxin-2 having the following amino acid sequence:A chain: (SEQ ID NO: 1) pGlu-Leu-Tyr-Ser-Ala-Leu-Ala-Asn-Lys-Cys-Cys-His- Val-Gly-Cys-Thr-Lys-Arg-Ser-Leu-Ala-Arg-Phe-Cys B chain: (SEQ ID NO: 2) Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys-Leu-Cys-Gly- Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly- Met-Ser-Thr-Trp-Ser; comprising the following steps:providing the amino acids necessary for the synthesis of the A and B chains with usual protective groups, wherein the cysteines are employed as trityl-protected amino acids (L-Cys(Trt)-OH);effecting a chromatographic purification of the individual chains A and B after the solid state synthesis;followed by the simultaneous folding and combination of the individual chains A and B in ammonium hydrogencarbonate buffer at pH 7.9 to 8.4; andsubsequent purification of the relaxin-2 formed.
摘要翻译: 具有以下氨基酸序列的人松弛素-2的制备方法:A链:(SEQ ID NO:1)pGlu-Leu-Tyr-Ser-Ala-Leu-Ala-Asn-Lys-Cys-Cys-His-Val -Gly-Cys-Thr-Lys-Arg-Ser-Leu-Ala-Arg-Phe-Cys B链:(SEQ ID NO:2)Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys- Leu-Cys-Gly-Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly-Met-Ser-Thr-Trp-Ser; 包括以下步骤:用通常的保护基提供合成A和B链所必需的氨基酸,其中半胱氨酸用作三苯甲基保护的氨基酸(L-Cys(Trt)-OH)); 在固态合成后进行单链A和B的色谱纯化; 然后在pH 7.9至8.4的同时折叠和组合各个链A和B在碳酸氢铵缓冲液中; 并随后纯化形成的松弛素-2。
-
5.
公开(公告)号:US20150038411A1
公开(公告)日:2015-02-05
申请号:US14380163
申请日:2013-02-22
申请人: Thomas Dschietzig
发明人: Thomas Dschietzig
IPC分类号: A61K38/22
CPC分类号: A61K38/2221 , A61K9/0019 , A61K9/1647
摘要: A pharmaceutical composition for treatment for of r afflicted or in risk of becoming of impaired glucose tolerance (IGT) and/or type-2 it comprising an effective amount of relaxin for protecting beta-cells and beta-cell function against the effects of high blood glucose (glucotoxicity). Treatment of persons of disglycaemias, and protection of beta cells of the islets of Langerhans and beta-cell function in patients having type-2 diabetes, is diclosed.
摘要翻译: 用于治疗患有葡萄糖耐量降低或有风险的药物组合物(IGT)和/或II型,其包含有效量的用于保护β-细胞的松弛素和针对高血液效应的β-细胞功能 葡萄糖(葡萄糖毒性)。 对2型糖尿病患者治疗糖尿病患者和保护胰岛细胞和β细胞功能的β细胞进行了分类。
-
公开(公告)号:US09434780B2
公开(公告)日:2016-09-06
申请号:US14234919
申请日:2012-08-03
IPC分类号: C07K14/64
摘要: A process for preparing human relaxin-2 having the following amino acid sequence: A chain: (SEQ ID NO: 1) pGlu-Leu-Tyr-Ser-Ala-Leu-Ala-Asn-Lys-Cys-Cys-His- Val-Gly-Cys-Thr-Lys-Arg-Ser-Leu-Ala-Arg-Phe-Cys B chain: (SEQ ID NO: 2) Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys-Leu-Cys-Gly- Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly- Met-Ser-Thr-Trp-Ser; comprising the following steps: providing the amino acids necessary for the synthesis of the A and B chains with usual protective groups, wherein the cysteines are employed as trityl-protected amino acids (L-Cys(Trt)-OH); effecting a chromatographic purification of the individual chains A and B after the solid state synthesis; followed by the simultaneous folding and combination of the individual chains A and B in ammonium hydrogencarbonate buffer at pH 7.9 to 8.4; and subsequent purification of the relaxin-2 formed.
-
-
-
-
-